You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Biological Activity for (±)-ADX 71743
(±)-ADX 71743 is a negative allosteric modulator at mGlu7 (IC50 = 300 nM). Blocks high frequency-induced LTP at SC-CA1 synapses in hippocampal slices in vitro. Increases evoked excitatory postsynaptic currents (eEPSCs) in mice. Brain penetrant.
Compound Libraries for (±)-ADX 71743
Technical Data for (±)-ADX 71743
|Storage||Store at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for (±)-ADX 71743
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions for (±)-ADX 71743
The following data is based on the product molecular weight 269.34. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||3.71 mL||18.56 mL||37.13 mL|
|5 mM||0.74 mL||3.71 mL||7.43 mL|
|10 mM||0.37 mL||1.86 mL||3.71 mL|
|50 mM||0.07 mL||0.37 mL||0.74 mL|
References for (±)-ADX 71743
References are publications that support the biological activity of the product.
Klar et al (2015) Activation of metabotropic glutamate receptor 7 is required for induction of long-term potentiation at SC-CA1 synapses in the hippocampus. J.Neurosci. 35 7600 PMID: 25972184
Tassin et al (2016) Phasic and tonic mGlu7 receptor activity modulates the thalamocortical network. Front Neural Circuits 10 31 PMID: 27199672
If you know of a relevant reference for (±)-ADX 71743, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: (±)-ADX 71743, (±)-ADX 71743 supplier, (±)-ADX, 71743, potent, negative, allosteric, modulators, NAMs, mGlu7, receptors, metabotropic, glutamate, epilepsy, 1431641-29-0, Glutamate, (Metabotropic), Group, III, Receptors, 5715, Tocris Bioscience
Citations for (±)-ADX 71743
Citations are publications that use Tocris products.
Currently there are no citations for (±)-ADX 71743. Do you know of a great paper that uses (±)-ADX 71743 from Tocris? Please let us know.
Reviews for (±)-ADX 71743
There are currently no reviews for this product. Be the first to review (±)-ADX 71743 and earn rewards!
Have you used (±)-ADX 71743?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.
Learning & Memory Poster
Recognition memory enables us to make judgements about whether or not we have encountered a particular stimulus before. This poster outlines the cellular mechanisms underlying recognition memory and its links to long-term depression, as well as the use of pharmacological intervention to assess the role of neurotransmitters in recognition memory.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.
Schizophrenia is a debilitating psychiatric disorder that affects 1% of the worldwide population. This poster describes the neurobiology of Schizophrenia, as well as highlighting the genetic and environmental factors that play a fundamental role in the etiology of the disease. The current and emerging drug targets are also discussed.